Literature DB >> 18243860

Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure.

Serge Masson1, Roberto Latini.   

Abstract

In patients with chronic heart failure (HF), amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are among the strongest independent predictors of hazard, and their measurement is useful for prognostication across the entire spectrum of HF disease severity. In patients with chronic HF, repeated determinations of NT-proBNP levels appear to convey additional prognostic value for relevant adverse outcomes, including death or HF hospitalization. Although "hard targets" for NT-proBNP values are not entirely defined, morbidity and mortality in chronic HF appear to increase markedly with an NT-proBNP concentration >1,000 ng/L. Confounding factors (such as renal function or obesity) should be kept in mind when prognostically evaluating patients using NT-proBNP measurements; however, the value of NT-proBNP is retained in these patients. Thus, serial assessment of NT-proBNP is valuable for prognostication in chronic HF in outpatients, and, as such, a measurement at each patient visit or the following of changes in clinical stability is recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18243860     DOI: 10.1016/j.amjcard.2007.11.024

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  National Academy of Clinical Biochemistry (NACB) laboratory medicine guidelines on the clinical utilization and analytical issues for cardiac biomarker testing in heart failure.

Authors:  John Beilby
Journal:  Clin Biochem Rev       Date:  2008-08

2.  Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

Authors:  Steven E Lipshultz; Tracie L Miller; Rebecca E Scully; Stuart R Lipsitz; Nader Rifai; Lewis B Silverman; Steven D Colan; Donna S Neuberg; Suzanne E Dahlberg; Jacqueline M Henkel; Barbara L Asselin; Uma H Athale; Luis A Clavell; Caroline Laverdière; Bruno Michon; Marshall A Schorin; Stephen E Sallan
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 3.  Prognostic value of combining echocardiography and natriuretic peptide levels in patients with heart failure.

Authors:  Wei-Hsian Yin; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Curr Heart Fail Rep       Date:  2012-06

Review 4.  Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Authors:  Sibo Tian; Kim M Hirshfield; Salma K Jabbour; Deborah Toppmeyer; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-10-09       Impact factor: 6.244

5.  Troponin T and pro-B-type natriuretic Peptide in fetuses of type 1 diabetic mothers.

Authors:  Noirin E Russell; Mary F Higgins; Michael Amaruso; Michael Foley; F M McAuliffe
Journal:  Diabetes Care       Date:  2009-08-18       Impact factor: 17.152

6.  Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment.

Authors:  Koichi Node; Teruo Inoue; Valentin Boyko; Ilan Goldberg; Enrique Z Fisman; Yehuda Adler; Ehud Schwammenthal; Zipora Matas; Solomon Behar; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-01-28       Impact factor: 9.951

7.  6 min walk test is a strong independent predictor of death in outpatients with heart failure.

Authors:  Morten Grundtvig; Torfinn Eriksen-Volnes; Stein Ørn; Eva Kjøl Slind; Lars Gullestad
Journal:  ESC Heart Fail       Date:  2020-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.